EXCALIBER-RRMM

Name No. For Patients with Purpose
EXCALIBER-RRMM 21-10

relapsed or refractory multiple myeloma

This study is to compare Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma


DREAMM-14

Name No. For Patients with Purpose
DREAMM-14 21-47

The target population for this study are patients with relapsed refractory multiple myeloma

This study is a phase 2, randomized, parallel, open-label study to investigate the safety, efficacy, and pharmacokinetics of various dosing regimens of single-agent Belantamab Mafodotin (GSK2857916) in participants with relapsed or refractory multiple myeloma


TAK-573-1501

Name No. For Patients with Purpose
TAK-573-1501 22-14

The target population for this study are patients with relapsed refractory multiple myeloma

This study is a phase 1/2, open-label study to investigate the safety and tolerability, efficacy, pharmacokinetics, and immunogenicity of Modakafusp Alfa (TAK-573) as a single agent in patients with relapsed refractory multiple myeloma


AFFIRM-AL

Name No. For Patients with Purpose
AFFIRM-AL 22-13

The target population for this study are Mayo Stage IV AL amyloid patients

This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients


Isa-RVD

Name No. For Patients with Purpose
Isa-RVD 19-34

The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria.

This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma


CPD-DARA

Name No. For Patients with Purpose
CPD-DARA 19-17

The target population for this study are patients with relapsed/refractory multiple myeloma (MM). Patients will have a confirmed diagnosis of MM, with measurable disease as per IMWG criteria, in the second relapse and beyond (third line of therapy and beyond)

This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma


MOR208C310

Name No. For Patients with Purpose
MOR208C310 20-35

Newly-diagnosed diffuse large B-cell lymphoma (DLBCL).

This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).


INDEPENDENCE ACE-536-MF-002

Name No. For Patients with Purpose
INDEPENDENCE ACE-536-MF-002 20-34

Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions.


HOVON 156

Name No. For Patients with Purpose
HOVON 156 19-16

Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy

This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy


HOVON 150

Name No. For Patients with Purpose
HOVON 150 19-18

Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy

This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy